Loading…

Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen

Abstract The aim of this study was to develop matrix-type transdermal systems (TDSs) containing the highly lipophilic (log P = 5.82) antiestrogen (AE) and the permeation enhancers propylene glycol and lauric acid. For that purpose, permeation of AE from various adhesive matrices through excised skin...

Full description

Saved in:
Bibliographic Details
Published in:Drug development and industrial pharmacy 2003-01, Vol.29 (7), p.785-793
Main Authors: Funke, Adrian Peter, Günther, Clemens, Müller, Rainer Helmut, Lipp, Ralph
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983
cites cdi_FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983
container_end_page 793
container_issue 7
container_start_page 785
container_title Drug development and industrial pharmacy
container_volume 29
creator Funke, Adrian Peter
Günther, Clemens
Müller, Rainer Helmut
Lipp, Ralph
description Abstract The aim of this study was to develop matrix-type transdermal systems (TDSs) containing the highly lipophilic (log P = 5.82) antiestrogen (AE) and the permeation enhancers propylene glycol and lauric acid. For that purpose, permeation of AE from various adhesive matrices through excised skin of hairless mice was evaluated. It was found that pretreatment of the skin with permeation enhancers raised the transdermal flux of subsequently applied antiestrogen. Highest steady-state transdermal fluxes (1.1 µg cm−2 h−1) were obtained from Gelva®, polyacrylate adhesive, followed by 0.55 µg cm−2 h−1 from Oppanol® polyisobutylene, 0.31 µg cm−2 h−1 from BIO-PSA® silicone, and 0.12 µg cm−2 h−1 from Sekisui polyacrylate matrices. In order to develop TDS with high content of fluid permeation enhancer propylene glycol, two different strategies were investigated. One strategy was the addition of hydroxypropyl cellulose (HPC) as thickening agent to Gelva matrices. This allowed for propylene glycol loading levels of up to 30%, resulting in transdermal AE fluxes of 0.09 µg cm−2 h−1. On the other hand, a fleece-laminated backing foil was loaded with the described permeation enhancer formulation and laminated with polyacrylate adhesive layer, resulting in transdermal AE fluxes of 0.06 µg cm−2 h−1. However, application of these TDSs on skin pretreated with permeation enhancers raised the fluxes to 2.6 µg cm−2 h−1 from Gelva HPC and 0.46 µg cm−2 h−1 from fleece Sekisui.
doi_str_mv 10.1081/DDC-120021778
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73525372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73525372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983</originalsourceid><addsrcrecordid>eNqF0bFv1DAUBnALgehRGFmRF7qF2nEcJ2N1BxTpKhjKwmK9OM-NKycOdq70_ntc3UHFUDG95feeP30m5C1nHzhr-Plmsy54yVjJlWqekRWXJSukqsvnZMVELYqWVfKEvErpljFetlK-JCd5slqIekV-bPAOfZhHnBYaLL2CJbp7-g0WM2CiNkR6HWFKPcYRPN2gd3cY9w8U6KW7Gfyebt0c5sF5Z-jFtDhMSww3OL0mLyz4hG-O85R8__Txen1ZbL9-_rK-2BamqtRSQGtQ8t5C3QmVg2FfNrxF0TdCVLVhAGibjnVSStEzZTm3aHjX2UrZnrWNOCVnh7tzDD93-XU9umTQe5gw7JJWQpZSqPK_kCvZ1lXDMiwO0MSQUkSr5-hGiHvNmX5oXefW9d_Ws393PLzrRuwf9bHmDN4fASQD3uZGjUuPrmplJVmVXXNwbsrNj_ArRN_rBfY-xD9L4qkM6p_VAcEvg4GI-jbs4pR_4In0vwGrMq6u</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17596480</pqid></control><display><type>article</type><title>Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen</title><source>EBSCOhost Business Source Ultimate</source><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Funke, Adrian Peter ; Günther, Clemens ; Müller, Rainer Helmut ; Lipp, Ralph</creator><creatorcontrib>Funke, Adrian Peter ; Günther, Clemens ; Müller, Rainer Helmut ; Lipp, Ralph</creatorcontrib><description>Abstract The aim of this study was to develop matrix-type transdermal systems (TDSs) containing the highly lipophilic (log P = 5.82) antiestrogen (AE) and the permeation enhancers propylene glycol and lauric acid. For that purpose, permeation of AE from various adhesive matrices through excised skin of hairless mice was evaluated. It was found that pretreatment of the skin with permeation enhancers raised the transdermal flux of subsequently applied antiestrogen. Highest steady-state transdermal fluxes (1.1 µg cm−2 h−1) were obtained from Gelva®, polyacrylate adhesive, followed by 0.55 µg cm−2 h−1 from Oppanol® polyisobutylene, 0.31 µg cm−2 h−1 from BIO-PSA® silicone, and 0.12 µg cm−2 h−1 from Sekisui polyacrylate matrices. In order to develop TDS with high content of fluid permeation enhancer propylene glycol, two different strategies were investigated. One strategy was the addition of hydroxypropyl cellulose (HPC) as thickening agent to Gelva matrices. This allowed for propylene glycol loading levels of up to 30%, resulting in transdermal AE fluxes of 0.09 µg cm−2 h−1. On the other hand, a fleece-laminated backing foil was loaded with the described permeation enhancer formulation and laminated with polyacrylate adhesive layer, resulting in transdermal AE fluxes of 0.06 µg cm−2 h−1. However, application of these TDSs on skin pretreated with permeation enhancers raised the fluxes to 2.6 µg cm−2 h−1 from Gelva HPC and 0.46 µg cm−2 h−1 from fleece Sekisui.</description><identifier>ISSN: 0363-9045</identifier><identifier>EISSN: 1520-5762</identifier><identifier>DOI: 10.1081/DDC-120021778</identifier><identifier>PMID: 12906336</identifier><language>eng</language><publisher>Colchester: Informa UK Ltd</publisher><subject>Adhesives - therapeutic use ; Administration, Cutaneous ; Animals ; Antiestrogen ; Biological and medical sciences ; Chemistry, Pharmaceutical - methods ; Estrogen Receptor Modulators - pharmacokinetics ; General pharmacology ; Highly lipophilic drug ; In Vitro Techniques ; Lauric acid ; Male ; Medical sciences ; Mice ; Mice, Hairless ; Permeability - drug effects ; Permeation enhancers ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Propylene glycol ; Propylene Glycol - pharmacokinetics ; Skin - metabolism ; Skin Absorption - drug effects ; Solubility ; Technology, Pharmaceutical - methods ; Time Factors ; Transdermal drug delivery systems (TDSs)</subject><ispartof>Drug development and industrial pharmacy, 2003-01, Vol.29 (7), p.785-793</ispartof><rights>2003 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2003</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983</citedby><cites>FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14954504$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12906336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Funke, Adrian Peter</creatorcontrib><creatorcontrib>Günther, Clemens</creatorcontrib><creatorcontrib>Müller, Rainer Helmut</creatorcontrib><creatorcontrib>Lipp, Ralph</creatorcontrib><title>Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen</title><title>Drug development and industrial pharmacy</title><addtitle>Drug Dev Ind Pharm</addtitle><description>Abstract The aim of this study was to develop matrix-type transdermal systems (TDSs) containing the highly lipophilic (log P = 5.82) antiestrogen (AE) and the permeation enhancers propylene glycol and lauric acid. For that purpose, permeation of AE from various adhesive matrices through excised skin of hairless mice was evaluated. It was found that pretreatment of the skin with permeation enhancers raised the transdermal flux of subsequently applied antiestrogen. Highest steady-state transdermal fluxes (1.1 µg cm−2 h−1) were obtained from Gelva®, polyacrylate adhesive, followed by 0.55 µg cm−2 h−1 from Oppanol® polyisobutylene, 0.31 µg cm−2 h−1 from BIO-PSA® silicone, and 0.12 µg cm−2 h−1 from Sekisui polyacrylate matrices. In order to develop TDS with high content of fluid permeation enhancer propylene glycol, two different strategies were investigated. One strategy was the addition of hydroxypropyl cellulose (HPC) as thickening agent to Gelva matrices. This allowed for propylene glycol loading levels of up to 30%, resulting in transdermal AE fluxes of 0.09 µg cm−2 h−1. On the other hand, a fleece-laminated backing foil was loaded with the described permeation enhancer formulation and laminated with polyacrylate adhesive layer, resulting in transdermal AE fluxes of 0.06 µg cm−2 h−1. However, application of these TDSs on skin pretreated with permeation enhancers raised the fluxes to 2.6 µg cm−2 h−1 from Gelva HPC and 0.46 µg cm−2 h−1 from fleece Sekisui.</description><subject>Adhesives - therapeutic use</subject><subject>Administration, Cutaneous</subject><subject>Animals</subject><subject>Antiestrogen</subject><subject>Biological and medical sciences</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Estrogen Receptor Modulators - pharmacokinetics</subject><subject>General pharmacology</subject><subject>Highly lipophilic drug</subject><subject>In Vitro Techniques</subject><subject>Lauric acid</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Hairless</subject><subject>Permeability - drug effects</subject><subject>Permeation enhancers</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Propylene glycol</subject><subject>Propylene Glycol - pharmacokinetics</subject><subject>Skin - metabolism</subject><subject>Skin Absorption - drug effects</subject><subject>Solubility</subject><subject>Technology, Pharmaceutical - methods</subject><subject>Time Factors</subject><subject>Transdermal drug delivery systems (TDSs)</subject><issn>0363-9045</issn><issn>1520-5762</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqF0bFv1DAUBnALgehRGFmRF7qF2nEcJ2N1BxTpKhjKwmK9OM-NKycOdq70_ntc3UHFUDG95feeP30m5C1nHzhr-Plmsy54yVjJlWqekRWXJSukqsvnZMVELYqWVfKEvErpljFetlK-JCd5slqIekV-bPAOfZhHnBYaLL2CJbp7-g0WM2CiNkR6HWFKPcYRPN2gd3cY9w8U6KW7Gfyebt0c5sF5Z-jFtDhMSww3OL0mLyz4hG-O85R8__Txen1ZbL9-_rK-2BamqtRSQGtQ8t5C3QmVg2FfNrxF0TdCVLVhAGibjnVSStEzZTm3aHjX2UrZnrWNOCVnh7tzDD93-XU9umTQe5gw7JJWQpZSqPK_kCvZ1lXDMiwO0MSQUkSr5-hGiHvNmX5oXefW9d_Ws393PLzrRuwf9bHmDN4fASQD3uZGjUuPrmplJVmVXXNwbsrNj_ArRN_rBfY-xD9L4qkM6p_VAcEvg4GI-jbs4pR_4In0vwGrMq6u</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>Funke, Adrian Peter</creator><creator>Günther, Clemens</creator><creator>Müller, Rainer Helmut</creator><creator>Lipp, Ralph</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20030101</creationdate><title>Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen</title><author>Funke, Adrian Peter ; Günther, Clemens ; Müller, Rainer Helmut ; Lipp, Ralph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adhesives - therapeutic use</topic><topic>Administration, Cutaneous</topic><topic>Animals</topic><topic>Antiestrogen</topic><topic>Biological and medical sciences</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Estrogen Receptor Modulators - pharmacokinetics</topic><topic>General pharmacology</topic><topic>Highly lipophilic drug</topic><topic>In Vitro Techniques</topic><topic>Lauric acid</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Hairless</topic><topic>Permeability - drug effects</topic><topic>Permeation enhancers</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Propylene glycol</topic><topic>Propylene Glycol - pharmacokinetics</topic><topic>Skin - metabolism</topic><topic>Skin Absorption - drug effects</topic><topic>Solubility</topic><topic>Technology, Pharmaceutical - methods</topic><topic>Time Factors</topic><topic>Transdermal drug delivery systems (TDSs)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Funke, Adrian Peter</creatorcontrib><creatorcontrib>Günther, Clemens</creatorcontrib><creatorcontrib>Müller, Rainer Helmut</creatorcontrib><creatorcontrib>Lipp, Ralph</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Drug development and industrial pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Funke, Adrian Peter</au><au>Günther, Clemens</au><au>Müller, Rainer Helmut</au><au>Lipp, Ralph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen</atitle><jtitle>Drug development and industrial pharmacy</jtitle><addtitle>Drug Dev Ind Pharm</addtitle><date>2003-01-01</date><risdate>2003</risdate><volume>29</volume><issue>7</issue><spage>785</spage><epage>793</epage><pages>785-793</pages><issn>0363-9045</issn><eissn>1520-5762</eissn><abstract>Abstract The aim of this study was to develop matrix-type transdermal systems (TDSs) containing the highly lipophilic (log P = 5.82) antiestrogen (AE) and the permeation enhancers propylene glycol and lauric acid. For that purpose, permeation of AE from various adhesive matrices through excised skin of hairless mice was evaluated. It was found that pretreatment of the skin with permeation enhancers raised the transdermal flux of subsequently applied antiestrogen. Highest steady-state transdermal fluxes (1.1 µg cm−2 h−1) were obtained from Gelva®, polyacrylate adhesive, followed by 0.55 µg cm−2 h−1 from Oppanol® polyisobutylene, 0.31 µg cm−2 h−1 from BIO-PSA® silicone, and 0.12 µg cm−2 h−1 from Sekisui polyacrylate matrices. In order to develop TDS with high content of fluid permeation enhancer propylene glycol, two different strategies were investigated. One strategy was the addition of hydroxypropyl cellulose (HPC) as thickening agent to Gelva matrices. This allowed for propylene glycol loading levels of up to 30%, resulting in transdermal AE fluxes of 0.09 µg cm−2 h−1. On the other hand, a fleece-laminated backing foil was loaded with the described permeation enhancer formulation and laminated with polyacrylate adhesive layer, resulting in transdermal AE fluxes of 0.06 µg cm−2 h−1. However, application of these TDSs on skin pretreated with permeation enhancers raised the fluxes to 2.6 µg cm−2 h−1 from Gelva HPC and 0.46 µg cm−2 h−1 from fleece Sekisui.</abstract><cop>Colchester</cop><pub>Informa UK Ltd</pub><pmid>12906336</pmid><doi>10.1081/DDC-120021778</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0363-9045
ispartof Drug development and industrial pharmacy, 2003-01, Vol.29 (7), p.785-793
issn 0363-9045
1520-5762
language eng
recordid cdi_proquest_miscellaneous_73525372
source EBSCOhost Business Source Ultimate; Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Adhesives - therapeutic use
Administration, Cutaneous
Animals
Antiestrogen
Biological and medical sciences
Chemistry, Pharmaceutical - methods
Estrogen Receptor Modulators - pharmacokinetics
General pharmacology
Highly lipophilic drug
In Vitro Techniques
Lauric acid
Male
Medical sciences
Mice
Mice, Hairless
Permeability - drug effects
Permeation enhancers
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Propylene glycol
Propylene Glycol - pharmacokinetics
Skin - metabolism
Skin Absorption - drug effects
Solubility
Technology, Pharmaceutical - methods
Time Factors
Transdermal drug delivery systems (TDSs)
title Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A27%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Matrix%20Patches%20for%20Transdermal%20Delivery%20of%20a%20Highly%20Lipophilic%20Antiestrogen&rft.jtitle=Drug%20development%20and%20industrial%20pharmacy&rft.au=Funke,%20Adrian%20Peter&rft.date=2003-01-01&rft.volume=29&rft.issue=7&rft.spage=785&rft.epage=793&rft.pages=785-793&rft.issn=0363-9045&rft.eissn=1520-5762&rft_id=info:doi/10.1081/DDC-120021778&rft_dat=%3Cproquest_cross%3E73525372%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17596480&rft_id=info:pmid/12906336&rfr_iscdi=true